All News
EULAR 2021 – Day 2 Report
During Day 2 there were great sessions devoted to RA, spondylarthritis, fatigue and more. Here are some of my highlights from Day 2.
Read Article
OP0227: Efficacy of Deucravactinib for PsA?
⭐️Deucrav = TYK2i.
⭐️Dr. Mease et al show MDA by wk16 + stat. signif improv in ACR20/50/70, enthes, & dactyl w/ deucrav vs PBO in pts w/ active PsA.
⭐️Incl crit: failed at least 1 csDMARD/NSAID/GC & up to 1 TNFi
#EULAR2021 @Rheumnow https://t.co/1jjsZIODFV
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#SLE and #Sjogren: is there a path for these to converge? Dr Martin-Guttierez used #MachineLearning to analyse blood & identified 2 endotypes. Both had different trajectory in disease activity & damage. May be useful to stratify appropriate therapy #EULAR2021 #POS0174 @RheumNow https://t.co/R4NMDJYVbY
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Better pics re JAKi retention better than bDMARDs in RA. But single site, ? Selection bias. Curves spread after 1st yr of Rx. Findings same if only 1st line adv Rx or adjusted for line of therapy POS0205 #EULAR2021 @RheumNow https://t.co/6HYpgVeyiw https://t.co/5mjpUFfWoG
Janet Pope Janetbirdope ( View Tweet)
Dr Eder reports population-based, matched cohort study 3 million people. IMID associated ⬆️ hospitalisation in COVID-19. OR 1.23, 95% CI 1.10, 1.37 @RheumNow #EULAR2021 Abstr#OP0285 https://t.co/KDK5j1Gg0X
Richard Conway RichardPAConway ( View Tweet)
Dr. Laura Coates discusses "what is fatigue" based on clinical outcome and disease activity measures in PsA. Three main groups stood out in predicting fatigue in these patients: level of inflammation, chronic pain, and chronicity of PsA disease. #EULAR2021 @RheumNow https://t.co/pFYRb1X7pT
Dr. Rachel Tate uptoTate ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, and Janssen. All content chosen by RheumNow and its faculty.
Dr. John Cush RheumNow ( View Tweet)
Check out our Lupus coverage from #EULAR2021
https://t.co/Gmh4sFv4Jl https://t.co/OihiiomZBd
Links:
Dr. John Cush RheumNow ( View Tweet)
#EULAR2021 How to Measure Success in Lupus? Dr. Kathryn Dao ( @KDAO2011 )
https://t.co/z8c8moIQCa https://t.co/0BLeFJyZD4
Links:
Dr. John Cush RheumNow ( View Tweet)
What's your EULAR IQ? Test your knowledge! #EULAR2021
https://t.co/psumBpzUc7 https://t.co/w5Vg68RVLs
Links:
Dr. John Cush RheumNow ( View Tweet)
Fecal Transplantation as Potential PsA Treatment: Dr. Eric Dein ( @ejdein1) #EULAR2021
https://t.co/ItYAEIJZSW https://t.co/uHnY9cWLEj
Links:
Dr. John Cush RheumNow ( View Tweet)
JAKi to #JAKi cycling is common in #rheumatoidarthritis Rx. Opal registry >53000 pts, 1/4 treated with JAKi (4000) & 44% new starts were Jaki. JAKi to JAKi cycling was >40%! POS0223 #EULAR2021 @RheumNow https://t.co/XV7wVJsE9c
Janet Pope Janetbirdope ( View Tweet)
"What we really need in SpA/PsA is personalized medicine in order to choose the best drug MOA for our patients." Dr. Laura Coates addressing paradox of choice in treatment options. I remain hopeful for better biomarkers for future precision medicine approach. #EULAR2021 @RheumNow https://t.co/nIDksfTe7h
Dr. Rachel Tate uptoTate ( View Tweet)
Turning the Corner on CV Risk in Rheumatoid Arthritis by Richard Conway ( @RichardPAConway) #EULAR2021
https://t.co/S0ownscRKv https://t.co/PJODe0U6wr
Links:
Dr. John Cush RheumNow ( View Tweet)
How Do You Measure Success When It Comes to SLE? by Dr. Kathryn Dao ( @KDAO2011 ) #EULAR2021
https://t.co/aVKY4B9CfW https://t.co/ffruCDouaE
Links:
Dr. John Cush RheumNow ( View Tweet)
#EULAR2021 Complex Immune Disturbances in ANA+ Individuals: Drs. Yusof and Hassan
https://t.co/nvSU7ArEUU https://t.co/7pJ5ypqDJn
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr Hellgren on pregnancy outcomes in RA 📈disease activity assoc preterm birth and small gestational age. Low disease activity = no increased risk compared controls @RheumNow #EULAR2021 Abstr#OP0210 https://t.co/L26xWhIFv6
Richard Conway RichardPAConway ( View Tweet)
Q-DAPSA for Measuring Disease Activity in PsA by Dr. Rachel Tate ( @uptoTate) #EULAR2021
https://t.co/fbi3Kbd2GS https://t.co/afRnle1EJK
Links:
Dr. John Cush RheumNow ( View Tweet)
DISCOVER 1&2: whole blood transcriptome in PsA: dysregulation of immune cell profiles vs. Ctrl
Guselkumab modulates genes expr towards normalization of immune cell composition. Would be interesting to look at STissue
signatures too 🧐 @StefanSiebert1 #POS0195 @Rheumnow #EULAR2021 https://t.co/7WChCP3U6W
Aurelie Najm AurelieRheumo ( View Tweet)
#EULAR2021 POS0226 Bimekizumab (anti-IL17A and IL-17F) 160 mg Q4w for AS, 3yr phase 2b, open-label extension wk 48-156). Efficacy sustained ASAS40 63%. AEs: pharyngitis, URI, bronchitis, ⬆️ ALT, oral candida (mild/mod). @RheumNow.
Eric Dein ejdein1 ( View Tweet)
